Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4793668 | 0.97 | HCRTR1 (0.44) | HCRTR1HCRTR2KDM4ESMN1; SMN2HTR2A | |
| SCHEMBL4794964 | 0.84 | HCRTR1 (0.44) | HCRTR1HCRTR2KDM4ESMN1; SMN2HTR2A | |
| SCHEMBL4771866 | 0.81 | HCRTR1 (0.44) | HCRTR1HCRTR2KDM4ESMN1; SMN2HTR2A | |
| SCHEMBL4768695 | 0.78 | HCRTR1 (0.73) | HCRTR1HCRTR2 | |
| SCHEMBL5068144 | 0.78 | HCRTR1 (0.52) | HCRTR1HCRTR2KDM4ESMN1; SMN2LTA4H | |
| SCHEMBL4773029 | 0.76 | HCRTR1 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL4777203 | 0.75 | HCRTR1 (0.54) | HCRTR1HCRTR2KDM4ESMN1; SMN2HTR2A | |
| SCHEMBL4775769 | 0.74 | KDM4E (0.44) | HCRTR1HCRTR2KDM4ESMN1; SMN2HTR2A | |
| SCHEMBL4777315 | 0.73 | HCRTR1 (0.46) | HCRTR1HCRTR2KDM4ESMN1; SMN2HTR2A | |
| SCHEMBL8256535 | 0.73 | HTR2A (0.42) | HCRTR1HCRTR2KDM4ESMN1; SMN2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | claimed |
| EP-1871752-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2006110626-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-19 | — | — | WO | claimed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885KDM4E 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.